Your session is about to expire
← Back to Search
Talimogene Laherparepvec for Soft Tissue Sarcoma
Study Summary
This trial is testing a new cancer treatment, talimogene laherparepvec, to see if it is safe and works well when combined with radiation.
- Soft Tissue Sarcoma
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Are there any analogous investigations that have explored Radiotherapy?
"Currently, 22 research studies are running on Radiotherapy. None of these projects have reached Phase 3 yet. Santa Monica in California is the primary hub for this form of treatment but other clinical sites around the world (242 total) host trials as well."
How many individuals are partaking in the research being conducted?
"This study is not taking enrolments at the present moment. The trial was initially posted on July 13th 2015 and saw its last update around May 4th 2022. However, if you are still looking for a clinical trial to participate in, there are 443 trials actively recruiting sarcoma patients while 22 studies require participants for radiotherapy-based treatments."
What is the ultimate purpose of this experiment?
"As stated by Amgen, the clinical trial's primary outcome will be Phase 1b: Number of Participants With Dose Limiting Toxicities (DLTs) and it will be tracked over a 14 week period. Additionally, they intend to measure secondary outcomes including Adverse Events (AEs), Overall Response Rate (ORR) as Measured by RECIST, and Overall Survival Rate (OS). The duration for data collection on OS is 5 years from the last enrollment date."
Is this medical study pioneering a new approach or has it been done before?
"Radiotherapy has been under the microscope since 2015, when a study sponsored by Amgen was conducted. After this initial research with 30 participants, Radiotherapy achieved Phase 1 and 2 drug approval. At present, 22 active trials are underway across 93 cities in 16 countries."
Is recruitment of participants still open for this research endeavor?
"This research is not currently in need of participants. The study was posted on July 13th 2015 and last updated May 4th 2022. If you are searching for another trial, 443 studies relating to sarcoma and 22 trials involving radiotherapy are actively taking candidates."
Share this study with friends
Copy Link
Messenger